Clinical Trial Update: Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituximab, Alemtuzumab, and GM-CSF as first-line therapy in early-stage chronic lymphocytic leukemia has completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2012-05-08